2001 JAN 11 - (NewsRx.com & NewsRx.net) -- AEterna Laboratories Inc. (AEL, AELA), Quebec City, Quebec, Canada, announced that the U.S. Food and Drug Administration (FDA) and the Canadian Health Authorities (HPB) have approved a pivotal trial of AE-941/Neovastat in the treatment of multiple myeloma patients.
This study is the third pivotal clinical trial AEterna has initiated in cancer in 2000. The trial will be conducted at some 20 hospitals throughout Canada, the United States, and select countries in Europe.
It will evaluate the efficacy of AEterna's anti-angiogenic treatment Neovastat in approximately 120 patients …
No comments:
Post a Comment